Asuragen to Present at 2018 American Society of Human Genetics Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Oct 9, 2018--Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will highlight its genetics product portfolio as part of the scientific poster session and will present at an Exhibitor Education Event hosted by Thermo Fisher Scientific at the 2018 American Society of Human Genetics (ASHG) Annual Meeting on October 16-20 in San Diego, California.
John Milligan, Ph.D., will present on behalf of Asuragen at the Thermo Fisher Scientific Exhibitor Education Event, “New Technologies Propelling Human Genetics and Reproductive Health Research,” from 12:30-1:45pm on Thursday, October 18 th. Dr. Milligan will review preliminary performance data of the AmplideX PCR/CE FMR1 *, SMN1 *, and SMN1/2 ** Kits on the SeqStudio Genetic Analyzer as part of the session.
Additionally, the company will present two posters as part of the scientific poster session on Wednesday, October 17 from 9:45-10:45am.
A unified PCR/CE carrier screening workflow for CFTR, SMN1, and FMR1 variants that consolidates the detection of SNVs, indels, CNVs, and triplet repeat expansions (Liangjing Chen, Ph.D.).
A rapid, high-throughput multiplex PCR/CE assay that reliably quantifies SMN1 copy number (John Milligan, Ph.D.).
“In 2018, we demonstrated the versatility and power of AmplideX technology as we extended our proprietary testing approach to several new inherited disease targets and applications, including DMPK and SMN1 ” said Matthew McManus, M.D., Ph.D., president and CEO of Asuragen. “This momentum will continue into 2019 as we launch products for the analysis of HTT, SMN1/2, and CFTR, providing simple, streamlined, and easy-to-implement solutions for challenging targets.”
The company will also have a presence at booth #1018 during the conference.
* For Research Use Only. Not for use in diagnostic procedures.
** Product in development. Specifications not finalized.
Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005319/en/
CONTACT: Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and CFO
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA TEXAS
INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE NANOTECHNOLOGY HEALTH BIOTECHNOLOGY GENETICS HOSPITALS MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL RESEARCH FDA SCIENCE MANAGED CARE
SOURCE: Asuragen, Inc.
Copyright Business Wire 2018.
PUB: 10/09/2018 08:00 AM/DISC: 10/09/2018 08:01 AM